Drug Profile
FolateImmune therapy - Endocyte/Purdue University
Alternative Names: Folate-conjugated vaccine - EndocyteLatest Information Update: 31 Dec 2018
Price :
$50
*
At a glance
- Originator Endocyte; Purdue University
- Developer Endocyte
- Class Cancer vaccines; Conjugate vaccines; Fluoresceins; Haptens; Imaging agents
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Renal cancer
Most Recent Events
- 21 Dec 2018 Endocyte has been acquired by Novartis
- 17 Dec 2013 Discontinued - Phase-I for Renal cancer in USA (SC)
- 11 Feb 2009 The phase II trial is discontinued due to a lower than expected rate of accrual but phase I trials continue in renal cell carcinoma